CRISPR Therapeutics is likely to witness an earnings beat as Casgevy sales climb and new CAR-T and in-vivo programs advance.

The ASX biotech sector ran strongly in October, but the big-cap thoroughbreds found the track conditions more challenging. ..

2. Mergers and acquisitions are picking up: So far this year, buyouts have boosted several biotech stocks. Some standouts: Regulus Therapeutics went up 120%; 89bio went up 85%; Chimerix gained 69% and ...

NurExone Biologic Inc. has been accepted into the BioFab Startup Lab, part of the Advanced Regenerative Manufacturing Institute’s BioFabUSA program, which supports early-stage biotech companies in ...

KB407 utilizes a replication-defective HSV-1 vector to deliver full-length CFTR to the airway epithelium. The interim readout ...

Novo Nordisk made a much higher offer to acquire a biotech Pfizer was already set to buy out. Losing this battle would be more damaging to Pfizer than to Novo Nordisk. Even so, both companies look ...

Thankfully, some companies can handle an inflationary environment and perform well throughout, while still registering the 12 ...

If you're an individual retail investor searching for healthcare stocks you can buy and hold for at least 20 years, here are ...

Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.